Experimental colon cancer tests pass FDA panel review

A committee of the US Food and Drug Administration (FDA) has decided the benefits outweigh the risks of 2 experimental tests that look for certain DNA changes (mutations) in cells that can cause colon cancer. One of the tests, Epi proColon developed by the German company Epigenomics, is a blood test that looks for DNA changes that can indicate cancer. The other test, Cologuard, made by the Wisconson-based company Exact Sciences, is a stool test that can find abnormalities that indicate cancer or pre-cancerous growths (polyps). Read more here.